If you or a family member uses Flovent HFA or another inhaled steroid to control asthma, this week’s news could affect how easily you get that medicine and how much it costs. The U.S. Food and Drug Administration has approved the first true generic version of Flovent HFA (fluticasone propionate) inhalation aerosol, 44 micrograms per actuation, for maintenance treatment of asthma in people aged 4 and older. This approval was granted to Glenmark Specialty SA and is intended to expand access to an important preventive inhaler.
Quick background: what Flovent HFA does
Flovent HFA is an inhaled corticosteroid used every day to reduce inflammation in the airways and help prevent asthma symptoms like wheezing, coughing, and shortness of breath. It is not a rescue inhaler for sudden attacks; instead, it’s a maintenance medicine that lowers the chance of flare-ups when used regularly. The brand product was discontinued by its manufacturer in late 2023, which left some patients and pediatricians worried about access and insurance coverage.
Why the FDA approval matters
- More competition usually lowers cost. Generic approvals typically increase supply and give insurers more options, which can reduce out-of-pocket costs for patients over time. The FDA emphasized that this approval is an important step toward expanding access to affordable asthma treatment.
- A true generic from a different company. Although there were authorized generics and other fluticasone products on the market, the FDA called this the first generic of Flovent HFA because it comes from a different manufacturer than the original brand. That distinction matters for insurance formularies and patient access.
- Same safety profile and warnings. The FDA notes that the generic’s prescribing information includes the same contraindications, warnings, and precautions as Flovent HFA. That means the same cautions about not using it for sudden severe asthma attacks and the same potential side effects, such as thrush in the mouth or effects on the immune system. Always follow your clinician’s instructions and the medication guide.
How the generic compares to the brand (simple table)
| Feature | Brand Flovent HFA (discontinued) | New generic (Glenmark) |
| Active ingredient | Fluticasone propionate 44 mcg/actuation | Fluticasone propionate 44 mcg/actuation |
| Intended use | Maintenance treatment of asthma in ages 4+ | Maintenance treatment of asthma in ages 4+ |
| Manufacturer | GlaxoSmithKline (brand discontinued) | Glenmark Specialty SA |
| Safety and warnings | Standard inhaled corticosteroid warnings | Same warnings and contraindications as brand |
| Availability impact | Limited after discontinuation; insurance issues | Expected to increase availability and affordability |
This table summarizes the main practical differences: the active medicine and intended use are the same, but the manufacturer and market effects differ. The FDA approval confirms the generic matches the brand in key clinical respects.
What patients and parents should know right now
- Don’t stop your inhaler without talking to your clinician. If you were using Flovent HFA or another inhaled steroid, sudden changes can increase the risk of asthma attacks. Any switch should be coordinated with your healthcare provider.
- Insurance coverage may still vary. Even with a generic approved, some insurance plans take time to update formularies. In the past, authorized generics and other fluticasone products were not always covered the same way, which caused access problems for some families. If you rely on a specific inhaler device (for age or technique), check with your insurer and pharmacist.
- Device differences can matter. Metered-dose inhalers (MDIs) like Flovent HFA deliver medicine differently than dry-powder inhalers. If your child or you need a particular device because of age or inhalation ability, confirm the generic’s device and practice using it with your clinician or pharmacist.
- Watch for side effects the same way you would with the brand. Common issues include throat irritation or oral thrush; rinsing the mouth after inhalation helps reduce that risk. If you notice new or worsening symptoms, contact your clinician.
Why pediatricians and asthma specialists were concerned
When the brand was discontinued, pediatricians reported that some children stopped using inhaled steroids because of supply and coverage problems. That raised concerns about increased asthma attacks and hospital visits. The new generic approval addresses one major barrier – availability from a different manufacturer – but it doesn’t instantly fix insurance or supply chain issues. Clinicians still report occasional problems getting the right product approved for a child’s age and inhaler technique.
Practical steps to take if you use Flovent or a similar inhaler
- Call your pharmacy to ask whether the new generic is in stock or expected soon. Pharmacies often know when a product will arrive and whether it will be billed as a generic or an authorized generic.
- Check your insurance formulary or contact member services to see if the generic will be covered and what your copay might be.
- Bring the inhaler to your next visit or ask your clinician to review proper inhaler technique with you or your child, especially if the device looks or feels different.
- Keep a rescue inhaler handy. Maintenance inhalers don’t treat sudden attacks; make sure your rescue plan is current and that you have quick-relief medication available.
A few things the FDA emphasized
The FDA framed this approval as part of its broader effort to increase access to safe, effective, and more affordable medicines. The agency also reminded clinicians and patients that the generic carries the same warnings and should not be used for acute severe asthma episodes. These are standard regulatory points, but they’re important reminders for everyday use.
What to watch next
- Availability at local pharmacies. Even after approval, distribution can take weeks. Glenmark indicated distribution would begin soon after approval; check with your pharmacy for timing.
- Insurance updates. Watch for formulary changes that could lower your cost. If coverage is delayed, ask your clinician about temporary alternatives and how to safely transition.
- Supply stability. The market has seen intermittent shortages for some inhalers in recent years; a single approval helps, but multiple manufacturers and steady production are what keep shelves stocked.
Better Treatment, Lower Cost – No Catch.
Find safer, more effective medications with fewer side effects – often for less money. It’s fast, free, and personalized. Learn More →
Sources (5)
- U.S. Food and Drug Administration, “\FDA approves first generic of Flovent HFA for treatment of asthma”
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-first-generic-flovent-hfa-treatment-asthma - American Academy of Pediatrics, “FDA approves first generic version of Flovent asthma inhaler”
https://publications.aap.org/aapnews/news/34603/FDA-approves-first-generic-version-of-Flovent - Mass.gov, “Discontinuation of Brand Flovent Products”
https://www.mass.gov/doc/issue-3-september-2023-0/download - Asthma and Allergy Foundation of America, “Flovent HFA and Flovent Diskus Asthma Medicines Being Discontinued”
https://community.aafa.org/blog/flovent-hfa-and-flovent-diskus-asthma-medicines-being-discontinued - EIN Presswire / Pharmaceutical Industry Today, “FDA approves first generic of Flovent HFA for treatment of asthma”
https://pharmaceuticals.einnews.com/pr_news/897312434/fda-approves-first-generic-of-flovent-hfa-for-treatment-of-asthma